Key clinical point: Bevacizumab is safe and highly effective for HHT bleeding.
Major finding: Mean hemoglobin increased by 3.2 g/dL, ESS decreased by a mean of 3.4 points, red blood cell units transfused decreased by 82%
Study details: An international observational cohort study of 238 patients
Disclosures: Dr. Al-Samkari reported receiving research support and/or consulting fees from Agios, Dova, and Amgen.
Al-Samkari H et al. ISTH 2020. Abstract OC 09.2.